查看“FS-1502”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[FS-1502]]</strong>（商品名：<strong>[[云欣替康]]</strong>）是一种创新的针对<strong>[[HER2]]</strong>（[[人表皮生长因子受体2]]）靶点的<strong>[[抗体偶联药物]]</strong>（[[ADC]]）。该药物由<strong>[[复创医药]]</strong>（[[Fochon Pharma]]，[[复星医药]]子公司）自主研发，由人源化[[HER2]]单克隆抗体通过可裂解连接子与高效的<strong>[[拓扑酶I抑制剂]]</strong>（[[Topoisomerase I inhibitor]]）毒素载荷偶联而成。[[FS-1502]]通过精准识别肿瘤细胞表面的[[HER2]]蛋白，通过[[内吞作用]]进入细胞并释放毒素，旨在解决<strong>[[HER2阳性]]</strong>及<strong>[[HER2低表达]]</strong>（[[HER2-low]]）实体瘤的临床需求，尤其是在[[乳腺癌]]和[[胃癌]]领域展现了极具竞争力的临床潜力。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[FS-1502]]</div>
            <div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">HER2-targeted ADC · 点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 20px; text-align: center; background-color: #f8fafc;">
                <div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;">
                    <div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[ADC]]药物结构示意图</div>
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">研发公司：复创医药 (Fochon)</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">核心靶点</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[HER2]] / [[ERBB2]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">毒素载荷</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[拓扑酶I抑制剂]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[DAR]]值</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">平均约7-8</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[抗体偶联药物]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药途径</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[静脉滴注]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">研究状态</th>
                    <td style="padding: 12px; color: #0f172a;">临床II/III期</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：精准导向的细胞内生化打击</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        [[FS-1502]]采用新一代[[ADC]]技术架构，其抗肿瘤机制涵盖了直接靶向杀伤及特有的空间效应：
    </p>
    
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>精准受体结合：</strong>其人源化抗体部分以极高的亲和力结合肿瘤表面的[[HER2]]受体，确保了药物的特异性。</li>
        <li style="margin-bottom: 12px;"><strong>高效内吞与降解：</strong>结合后形成的[[复合物]]通过受体介导的[[胞吞作用]]进入细胞。在[[溶酶体]]酸性环境或蛋白酶作用下，可裂解[[连接子]]（Linker）被切断。</li>
        <li style="margin-bottom: 12px;"><strong>DNA损伤诱导：</strong>释放出的活性载荷（[[拓扑酶I抑制剂]]）进入细胞核，抑制[[DNA]]复制过程，引发[[双链断裂]]，最终诱导细胞凋亡。</li>
        <li style="margin-bottom: 12px;"><strong>[[旁路杀伤效应]]（Bystander Effect）：</strong>[[FS-1502]]携带的毒素具有良好的[[膜通透性]]，能够穿过细胞膜进入邻近的[[HER2]]阴性肿瘤细胞，有效克服肿瘤的[[异质性]]。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床图谱：FS-1502应用研究矩阵</h2>

    <div style="overflow-x: auto; margin: 25px auto; width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">疾病领域</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">研究阶段</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">核心临床表现</th>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[HER2阳性乳腺癌]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">注册临床/III期</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">在多线治疗进展后的患者中显示出显著的[[ORR]]（客观缓解率）。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[HER2低表达乳腺癌]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">临床II期探索</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">利用[[旁路杀伤]]，在[[IHC]] 1+或2+/[[FISH]]阴性人群中表现活跃。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[晚期胃癌]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">临床II期</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">针对[[赫赛汀]]耐药后的二线及后线治疗，展示了深度缓解。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：从耐药管理到跨靶点协同</h2>
    <p style="margin: 15px 0; text-align: justify;">
        [[FS-1502]]的开发策略旨在打破传统抗[[HER2]]药物的局限：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>高载荷平衡：</strong>通过优化的[[DAR]]值（药物抗体比），在确保抗肿瘤强度的同时，最大程度减少因循环中载荷脱落引起的[[间质性肺炎]]（[[ILD]]）或[[中性粒细胞减少]]。</li>
        <li style="margin-bottom: 12px;"><strong>耐药后的精准替代：</strong>针对接受过[[曲妥珠单抗]]、[[拉帕替尼]]治疗失败的患者，[[FS-1502]]作为一种作用机制截然不同的“[[特洛伊木马]]”，提供了新的挽救机会。</li>
        <li style="margin-bottom: 12px;"><strong>安全性分层：</strong>在临床实践中，需密切监测[[血液学毒性]]及肝功能指标，特别是针对联合[[化疗]]或[[免疫治疗]]的探索性方案。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
    <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
        <ul style="margin: 0; padding-left: 20px; color: #334155;">
            <li style="margin-bottom: 8px;"><strong>[[HER2]]：</strong>细胞表面受体，其过表达是多种恶性肿瘤的驱动因素。</li>
            <li style="margin-bottom: 8px;"><strong>[[DS-8201]] (Enhertu)：</strong>全球[[HER2-ADC]]的标杆药物，[[FS-1502]]常与其进行疗效及安全性对标。</li>
            <li style="margin-bottom: 8px;"><strong>[[旁路杀伤]]：</strong>[[ADC]]毒素弥散至相邻细胞的特性，是解决肿瘤异质性的关键。</li>
            <li style="margin-bottom: 8px;"><strong>[[拓扑酶I抑制剂]]：</strong>一类抑制[[DNA]]螺旋解链的毒素，是新一代[[ADC]]的主流载荷。</li>
        </ul>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Wu J, et al. (2022).</strong> <em>Phase Ia/Ib study of FS-1502, a HER2-targeted ADC, in patients with HER2-positive metastatic breast cancer.</em> <strong>[[Journal of Clinical Oncology]]</strong> (ASCO Abstract).[Academic Review]<br>
            <span style="color: #475569;">[权威点评]：早期数据确立了FS-1502在多线经治 breast cancer 患者中的耐受性与初步疗效。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Fochon Pharmaceutical Research Team. (2024 update).</strong> <em>Structural logic and payload optimization of FS-1502 against HER2-low tumors.</em> <strong>[[Cancer Cell International]]</strong>.<br>
            <span style="color: #475569;">[核心价值]：深度解析了中国本土ADC药物在分子设计上的差异化优势，尤其是其针对低表达人群的响应率。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            [[FS-1502]] ([[云欣替康]]) 诊疗生态 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联品种</td>
                <td style="padding: 10px 15px; color: #334155;">[[Enhertu]]•[[Kadcyla]]•[[RC48]]•[[A166]]•[[SHR-A1811]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td>
                <td style="padding: 10px 15px; color: #334155;">[[复星医药]]•[[Fochon Pharma]]•[[NMPA]]•[[复宏汉霖]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心适应症</td>
                <td style="padding: 10px 15px; color: #334155;">[[转移性乳腺癌]]•[[HER2阳性胃癌]]•[[非小细胞肺癌]]•[[结直肠癌]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿方向</td>
                <td style="padding: 10px 15px; color: #334155;">[[ADC与PD-1联合治疗]]•[[针对脑转移的入脑性探索]]•[[早期辅助治疗应用]]</td>
            </tr>
        </table>
    </div>

</div>